Literature DB >> 11407477

Expression of the endothelin-B receptor in pigment cell lesions of the skin. Evidence for its role as tumor progression marker in malignant melanoma.

A Demunter1, C De Wolf-Peeters, H Degreef, M Stas, J J van den Oord.   

Abstract

Endothelins (ETs) exert several functions in human melanocytes, including proliferation, dendrite formation, and melanin synthesis. Among the ET receptors, the non-selective endothelin-B (ETB) receptor is the major receptor in melanocytes and malignant melanoma (MM) cells. In spite of the important role of ETs and their receptors in the growth and differentiation of melanocytes, the distribution and expression levels of ETB receptors in tissue sections of benign and malignant pigment cell lesions is still unknown. We combined immunohistochemistry and reverse transcriptase-polymerase chain reaction (RT-PCR) to study ETB receptor expression in benign and malignant pigment cell lesions and in normal skin. Immunohistochemistry on paraffin-embedded tissue sections of 159 cases revealed a significant increase in intensity of ETB receptor expression from common nevi over dysplastic nevi and primary MM to metastatic MM. Quantitative PCR using realtime detection on 75 samples confirmed the immunohistochemical results. These data add the ETB receptor to the growing list of tumor progression markers in MM and suggest that ETs play a role in the progression of MM in the skin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11407477     DOI: 10.1007/s004280000362

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  40 in total

1.  Rendomab B4, a monoclonal antibody that discriminates the human endothelin B receptor of melanoma cells and inhibits their migration.

Authors:  Aurélie Borrull; Bertrand Allard; Anne Wijkhuisen; Amaury Herbet; Patricia Lamourette; Wided Birouk; Denis Leiber; Zahra Tanfin; Frédéric Ducancel; Didier Boquet; Jean-Yves Couraud; Philippe Robin
Journal:  MAbs       Date:  2016-07-08       Impact factor: 5.857

2.  HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma.

Authors:  Fernanda Faião-Flores; Michael F Emmons; Michael A Durante; Fumi Kinose; Biswarup Saha; Bin Fang; John M Koomen; Srikumar P Chellappan; Silvya Stuchi Maria-Engler; Uwe Rix; Jonathan D Licht; J William Harbour; Keiran S M Smalley
Journal:  Clin Cancer Res       Date:  2019-06-21       Impact factor: 12.531

Review 3.  Endothelin B receptor, a new target in cancer immune therapy.

Authors:  Lana E Kandalaft; Andrea Facciabene; Ron J Buckanovich; George Coukos
Journal:  Clin Cancer Res       Date:  2009-06-30       Impact factor: 12.531

4.  A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma.

Authors:  Richard Kefford; Jane McNeil Beith; Guy Arthur Van Hazel; Michael Millward; James Marshall Trotter; David Keith Wyld; Rada Kusic; Revati Shreeniwas; Adele Morganti; Andrea Ballmer; Eleonor Segal; Oliver Nayler; Martine Clozel
Journal:  Invest New Drugs       Date:  2006-10-05       Impact factor: 3.850

Review 5.  Role of the endothelin axis and its antagonists in the treatment of cancer.

Authors:  A Bagnato; M Loizidou; B R Pflug; J Curwen; J Growcott
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

6.  Generation and characterization of rendomab-B1, a monoclonal antibody displaying potent and specific antagonism of the human endothelin B receptor.

Authors:  Bertrand Allard; Anne Wijkhuisen; Aurélie Borrull; Frédérique Deshayes; Fabienne Priam; Patricia Lamourette; Frédéric Ducancel; Didier Boquet; Jean-Yves Couraud
Journal:  MAbs       Date:  2012-12-05       Impact factor: 5.857

7.  A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy.

Authors:  Richard F Kefford; Philip R Clingan; Benjamin Brady; Andrea Ballmer; Adele Morganti; Peter Hersey
Journal:  Mol Cancer       Date:  2010-03-30       Impact factor: 27.401

8.  Protein interaction network topology uncovers melanogenesis regulatory network components within functional genomics datasets.

Authors:  Hsiang Ho; Tijana Milenković; Vesna Memisević; Jayavani Aruri; Natasa Przulj; Anand K Ganesan
Journal:  BMC Syst Biol       Date:  2010-06-15

9.  Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1alpha in melanoma cells.

Authors:  Francesca Spinella; Laura Rosanò; Martina Del Duca; Valeriana Di Castro; Maria Rita Nicotra; Pier Giorgio Natali; Anna Bagnato
Journal:  PLoS One       Date:  2010-06-21       Impact factor: 3.240

10.  High-incidence spontaneous tumors in JF1/Ms mice: relevance of hypomorphic germline mutation and subsequent promoter methylation of Ednrb.

Authors:  Junko Watanabe; Yasuhiko Kaneko; Masafumi Kurosumi; Yasuhito Kobayashi; Michihiro Sakamoto; Mitsuaki A Yoshida; Miho Akiyama; Yoshibumi Matsushima
Journal:  J Cancer Res Clin Oncol       Date:  2013-11-06       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.